


ISCI, Volume 19

Supplemental Information


**Safety of Whole-Body Abrogation
of the TRF1 Shelterin Protein in Wild-Type
and Cancer-Prone Mouse Models**

Leire Bejarano, Jessica Louzame, Juan José Montero, Diego Megías, Juana M. Flores, and Maria A. Blasco


A




B




C







A



A



B



1 **Supplementary figure legends**
2

3 **Supplementary Figure 1. PCR analysis of *Trf1* deletion upon tamoxifen**
4 **treatment. Related to Figure 1. (A)** Analysis of *Trf1* excision by PCR in *Ink4Arf*-
5 deficient mice. **(B)** Analysis of *Trf1* excision by PCR in *p53*-deficient mice. **(C)** Analysis
6 of *Trf1* excision by PCR in wild-type background.
7

8 **Supplementary Figure 2. Telomere length analysis upon *Trf1* deletion in the**
9 **different genetic backgrounds. Related to Figure 1. (A)** Telomere Q-FISH analysis
10 in the intestine of the indicated genotypes. Data are represented as mean \pm SEM. n
11 represents number of mice. Statistical analysis: unpaired *t*-test.
12

13 **Supplementary Figure 3. *Trf1* deletion does not decrease brain stem cell markers.**
14 **Related to Figure 6. (A)** Representative images (up) and quantification (down) of
15 Sox2 -positive cells in the brain after *Trf1* deletion in the indicated backgrounds. Scale
16 bar 20 μ M. Data are represented as mean \pm SEM. n represents number of mice.
17 Statistical analysis: unpaired *t*-test.
18

19 **Supplementary Figure 4. Tumor histology in *InkArf*-deficient and *p53*-deficient**
20 **mice. Related to Figure 7. (A)** Representative images of the different tumor types by
21 H&E at the human end-point. Scale bar 100 μ M. **(B)** Representative images of the
22 different tumor types by H&E at the human end-point. Scale bar 20 μ M.
23
24
25

26 **Transparent Methods**

27

28 **Mice**

29 *Trf1^{lox/lox}* mice (Martínez *et al.*, 2009) were crossed with a mouse strain carrying
30 ubiquitously expressed, tamoxifen-activated recombinase, *hUBC-CreERT2*
31 (Ruzankina *et al.*, 2007) to generate *Trf1^{lox/lox}* or *Trf1^{+/+}*, *hUBC-CreERT2* mice. These
32 mice were further crossed with *Ink4Arf^{-/-}* (Serrano *et al.*, 1996) and *p53^{-/-}* (Jacks *et al.*,
33 1994) mouse lines to generate *Trf1^{+/+}* or *Trf1^{lox/lox}*, *hUBC-CreERT2*, *Ink4Arf^{-/-}* and
34 *Trf1^{+/+}* or *Trf1^{lox/lox}*, *hUBC-CreERT2*, *p53^{-/-}* mice. These mice were fed *ad libitum* with
35 tamoxifen containing diet for long-term, starting at 6 weeks of age for *p53*-deficient
36 background and 10-weeks of age for *Ink4Arf*-deficient and wild type backgrounds.
37 *p53*-deficient mice started tamoxifen treatment earlier due to the shorter lifespan of
38 this mice. All mice were maintained at the Spanish National Cancer Centre under
39 specific pathogen-free conditions in accordance with the recommendations of the
40 Federation of European Laboratory Animal Science Associations (FELASA). All
41 animal experiments were approved by the Ethical Committee (CElyBA) from the
42 Spanish National Cancer Centre and performed in accordance with the guidelines
43 stated in the International Guiding Principles for Biomedical Research Involving
44 Animals, developed by the Council for International Organizations of Medical Sciences
45 (CIOMS).

46

47 **Immunofluorescence analyses in tissue sections**

48 For immunofluorescence analyses, tissues were fixed in 10% buffered formalin
49 (Sigma) and embedded in paraffin. After desparaffination and citrate antigen retrieval,

50 sections were permeabilized with 0.5% Triton in PBS and blocked with 1%BSA and
51 10% Australian FBS (GENYCELL) in PBS.

52 Rat polyclonal anti-TRF1 antibody (homemade) was applied overnight in
53 antibody diluents with background reducing agents (Invitrogen). Anti-rat Alexa 555
54 secondary antibody (Life Technologies, S.A) was incubated 1 hr at room temperature
55 also in antibody diluents with background reducing agents (Invitrogen).

56 Immunofluorescence images were obtained using a confocal ultraspectral
57 microscope (Leica TCS-SP5). Quantifications were performed with Definiens
58 software.

59

60 **Immunohistochemistry analyses in tissue sections**

61 For immunohistochemistry analyses, tissues were fixed in 10% buffered
62 formalin (Sigma) and embedded in paraffin. Immunohistochemistry was performed on
63 de-paraffinated tissue sections processed with 10 mM sodium citrate (pH 6.5) cooked
64 under pressure for 2 min. Slides were washed in water, then in Buffer TBS Tween20
65 0.5 %, blocked with peroxidase, washed with TBS Tween20 0.5 % again and blocked
66 with fetal bovine serum followed by another wash.

67 Primary antibodies included those raised against: γ H2AX Ser 139 (Millipore),
68 Ki67 (Master diagnostica), Sox2 (C70B1, Cell signaling) and Nestin (RAT-401,
69 Millipore). Slides were then incubated with secondary antibodies conjugated with
70 peroxidase from DAKO.

71 Pictures were taken using Olympus AX70 microscope. The percentage of
72 positive cells was identified by eye.

73

74 **Histological analyses in tissue sections**

75 Tissue samples were fixed overnight in 10% neutral buffered formalin,
76 embedded in paraffin and sectioned 3 μ m thick and dried. Slides were dewaxed and
77 re-hydrated through a series of graded ethanol until water and were stained with
78 hematoxylin-eosin (H-E). Histological observations and photomicrography were
79 performed using an Olympus DP73 digital camera. Histopathologies were classified
80 into “non-tumoral” lesions, “preneoplastic” lesions and tumor lesions.

81 “Non-tumoral” lesions included degenerative lesions (atrophy in both epidermis
82 and hypodermis, dermal fibrosis, follicular atrophy), inflammatory lesions (dermatitis,
83 hepatitis) and proliferative lesion (benign hyperplasias, hyperkeratosis).

84 “Pre-neoplastic” lesions were mainly proliferative and included epithelial
85 dysplasia, malignant hyperplasia, nuclear atypia and cell depolarization.

86 Tumor lesions were characterized by cellular polymorphism, irregular
87 stratification, both loss of polarity or basement membrane disruption of epithelial cells,
88 nuclear hyperchromatism, nuclear atypia, enlarged nucleoli, increase number of
89 mitotic figures and atypical mitotic figures. The most frequent tumors were lymphomas
90 (in thymus or extending and infiltrating different organs, mainly the spleen, liver, and
91 lymph nodes), histiocytic sarcomas (in liver, spleen and mesenteric lymph nodes),
92 subcutaneous fibrosarcomas and angiosarcomas, vertebral osteosarcomas and
93 squamous cell carcinomas (SCC) in skin.

94

95 **Telomere length analyses on tissue sections**

96 For quantitative telomere fluorescence *in situ* hybridization (Q-FISH) we
97 deparaffinized paraffin-embedded sections and fixed them with 4% formaldehyde,
98 followed by digestion with pepsine/HCl and a second fixation with 4% formaldehyde.
99 Next, we dehydrated the sides with increasing concentrations of EtOH (70%, 90%,

100 100%) and incubated them with the telomeric probe for 3.5 min at 85°C followed by
101 2h RT incubation in a wet chamber. After, the slides were extensively washed with
102 50% formamide and 0.08% TBS-Tween. Immunofluorescence images were obtained
103 using a confocal ultraspectral microscope (Leica TCS-SP5) and the analysis was
104 performed by Definiens software.

105

106 **Real-time qPCR**

107 Total RNA from frozen tissue was extracted with the RNeasy kit (QIAGEN)
108 following manufacturer's instructions. The cDNA synthesis was performed using the
109 iSCRIPT cDNA synthesis kit (BIO-RAD) according to manufacturer's protocols.

110 Quantitative real-time PCR was performed with the QuantStudio 6 Flex (Applied
111 Biosystems, Life Technologies) using Go-Taq qPCR master mix (Promega). All values
112 were obtained in triplicates.

113 Primers for mouse samples are listed below:

114 TRF1-F 5'-GTCTCTGTGCCGAGCCTTC-3'

115 TRF1-R 5'-TCAATTGGTAAGCTGTAAGTCTGTG-3'

116 TBP1-F 5'-ACCCTTCACCAATGACTCCTATG-3'

117 TBP1-R 5'-TGACTGCAGCAAATCGCTTGG-3'

118

119 **PCR**

120 DNA from frozen tissue samples was extracted using
121 Phenol:Chloroform:Isoamyl:Alcohol (Sigma). Cre-mediated recombination by PCR
122 was determined using the following primers:

123 F: 5'-ATAGTGATCAAAATGTGGTCCTGGG-3'

124 R: 5'-GCTTGCCAAATTGGGTTGG-3'

125

126 **Quantification and statistical analysis**

127 Survival data were analyzed by Kaplan Meier survival curves, and comparisons
128 were performed by *Log Rank* test. Statistical analysis was performed using GraphPad
129 Prism 5.03. Comparison of the percentage of mice in Figures 3, 4, 5, 7 and 8 was
130 performed by *Chi-Square* test.

131 Immunofluorescence quantifications were performed with Definiens software
132 and immunohistochemistry quantifications were performed by direct cell counting.
133 *Unpaired Student's t test* was used to determine statistical significance. P values of
134 less than 0.05 were considered significant. Statistical analysis was performed using
135 Microsoft® Excel 2011.

136

137

138 **References**

139

140 Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T.
141 and Weinberg, R. A. (1994) 'Tumor spectrum analysis in p53-mutant mice', *Current*
142 *Biology*, 4(1), pp. 1–7. doi: 10.1016/S0960-9822(00)00002-6.

143 Martínez, P., Thanasoula, M., Muñoz, P., Liao, C., Tejera, A., McNees, C., Flores, J.
144 M., Fernández-Capetillo, O., Tarsounas, M. and Blasco, M. A. (2009) 'Increased
145 telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative
146 pathologies and increased cancer in mice', *Genes and Development*, 23(17), pp.
147 2060–2075. doi: 10.1101/gad.543509.

148 Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis, G.,
149 Zediak, V. P., Velez, M., Bhandoola, A. and Brown, E. J. (2007) 'Deletion of the
150 Developmentally Essential Gene ATR in Adult Mice Leads to Age-Related Phenotypes
151 and Stem Cell Loss', *Cell Stem Cell*, 1(1), pp. 113–126. doi:
152 10.1016/j.stem.2007.03.002.

153 Serrano, M., Lee, H. W., Chin, L., Cordon-Cardo, C., Beach, D. and DePinho, R. A.
154 (1996) 'Role of the INK4a locus in tumor suppression and cell mortality', *Cell*, 85(1),
155 pp. 27–37. doi: 10.1016/S0092-8674(00)81079-X.

156

157

158

159

160

161

162